Regulatory & Policy
Just 1 of 19 matched new substances from US and EU regulators had a Gulf trial site
Camizestrant was the only one, with 2 registered studies at sites in the UAE. The US approved 9 new molecular entities and new biologics in September, 6 of them under priority review.
19 Oct 2026 · 7 min read
